ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 4.9 | 5.7 | 7.6 |
| Other income | 0.2 | 0.1 | 4.3 |
| Total income | 5.1 | 5.8 | 12.0 |
| Profit before exceptional items & tax | -1.6 | -1.2 | 4.0 |
| Profit before tax | -1.6 | -1.2 | 4.0 |
| Net profit | -1.6 | -1.2 | 4.0 |
| Operating margin | -31.4% | -20.7% | 33.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -35.50% |
|---|
BSE results filing, NSE: TCMLMTD. Figures extracted from the filing.
TCM Ltd: key numbers
- Share price
- ₹47.20
- Market cap
- ₹35.30 Cr
- Revenue (annual)
- ₹19.74 Cr
- Net profit (annual)
- ₹-5.81 Cr
- P/E (TTM)
- -6.8×Sector 35.5×
- Promoter holding
- 49.51%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from TCM Ltd
All →TCM Q2 FY27 Results: Net Loss of ₹0.8 Cr, Loss Widens
TCM Ltd reported revenue from operations of ₹6 Cr (+1.7% YoY) and a net loss of ₹0.8 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.8 Cr
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
TCM Other Announcement
TCM Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. This is a routine regulatory disclosure under SEBI Regulation 31(1)(b).
TCM Annual General Meeting
TCM Limited held its 82nd Annual General Meeting on September 25, 2026. Shareholders approved financial statements and the reappointment of several directors.
TCM Merger & Restructuring
TCM Limited signed an MoU to form a JV for a villa project in Ernakulam with Asset Homes Pvt Ltd. No financial terms finalized.
TCM Merger & Restructuring Worth ₹25 Cr
TCM Ltd signed an MOU to form a JV SPV for a Kalamassery villa project. Investor Suhas Nandan will inject Rs 25 Crore loan capital.
- Value
- ₹25.00 Cr
- Execution
- 3 years (loan return period; max 4 years from disbursement)